APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nocturia

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nocturia Market Analysis and Forecast 2026-2032

29 December 2025212 pages

Choose your research edition.

Industry ResearchNocturia Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Nocturia Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Nocturia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nocturia Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Nocturia Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Nocturia market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nocturia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nocturia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nocturia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nocturia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nocturia include Abbott, Allergan, APOTEX INC, Astellas Pharma, Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Ferring Pharmaceuticals and GlaxoSmithKline, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nocturia, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nocturia, also provides the revenue of main regions and countries. Of the upcoming market potential for Nocturia, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nocturia revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nocturia market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nocturia revenue, projected growth trends, production technology, application and end-user industry.

Nocturia Segment by Company

Abbott

Allergan

APOTEX INC

Astellas Pharma

Astra Zeneca

Bristol-Myers Squibb

Eli Lilly

Ferring Pharmaceuticals

GlaxoSmithKline

Johnson & Johnson

Merck

Mylan

Novartis

Pfizer

Rechon Life Science AB

Sagent Pharmaceuticals

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva

Chengdu Leer Pharmaceutical

Fosun Pharma

Hainan Zhonghe Pharmaceutical

Nanjing Xingyin Pharmaceutical Group

Hybio Pharmaceutical

Zhejiang Conba Pharmaceutical

Nocturia Segment by Type

Desmopressin

Diuretics

Anticholinergic Drugs

Alpha Blockers

Others

Nocturia Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Nocturia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nocturia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nocturia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nocturia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nocturia in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nocturia company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nocturia revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nocturia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Desmopressin Major Player Table 3. Diuretics Major Player Table 4. Anticholinergic Drugs Major Player Table 5. Alpha Blockers Major Player Table 6. Others Major Player Table 7. Global Nocturia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Retail Pharmacies Major Player Table 9. Online Pharmacies Major Player Table 10. Hospital Pharmacies Major Player Table 11. Nocturia Industry Trends Table 12. Nocturia Industry Drivers Table 13. Nocturia Industry Opportunities and Challenges Table 14. Nocturia Industry Restraints Table 15. Global Nocturia Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nocturia Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nocturia Market Share by Region (2021-2026) Table 18. Global Nocturia Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nocturia Market Share by Region (2027-2032) Table 20. Global Nocturia Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nocturia Revenue Market Share by Players (2021-2026) Table 22. Global Nocturia Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nocturia Key Players Headquarters & Area Served Table 24. Global Nocturia Players, Product Type & Application Table 25. Global Nocturia Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nocturia by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nocturia Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nocturia Revenue Market Share by Type (2021-2026) Table 32. Global Nocturia Revenue Market Share by Type (2027-2032) Table 33. Global Nocturia Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nocturia Revenue Market Share by Application (2021-2026) Table 37. Global Nocturia Revenue Market Share by Application (2027-2032) Table 38. Abbott Company Information Table 39. Abbott Business Overview Table 40. Abbott Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Abbott Nocturia Product Portfolio Table 42. Abbott Recent Development Table 43. Allergan Company Information Table 44. Allergan Business Overview Table 45. Allergan Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Allergan Nocturia Product Portfolio Table 47. Allergan Recent Development Table 48. APOTEX INC Company Information Table 49. APOTEX INC Business Overview Table 50. APOTEX INC Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. APOTEX INC Nocturia Product Portfolio Table 52. APOTEX INC Recent Development Table 53. Astellas Pharma Company Information Table 54. Astellas Pharma Business Overview Table 55. Astellas Pharma Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Astellas Pharma Nocturia Product Portfolio Table 57. Astellas Pharma Recent Development Table 58. Astra Zeneca Company Information Table 59. Astra Zeneca Business Overview Table 60. Astra Zeneca Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Astra Zeneca Nocturia Product Portfolio Table 62. Astra Zeneca Recent Development Table 63. Bristol-Myers Squibb Company Information Table 64. Bristol-Myers Squibb Business Overview Table 65. Bristol-Myers Squibb Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Bristol-Myers Squibb Nocturia Product Portfolio Table 67. Bristol-Myers Squibb Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Eli Lilly Nocturia Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Ferring Pharmaceuticals Company Information Table 74. Ferring Pharmaceuticals Business Overview Table 75. Ferring Pharmaceuticals Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Ferring Pharmaceuticals Nocturia Product Portfolio Table 77. Ferring Pharmaceuticals Recent Development Table 78. GlaxoSmithKline Company Information Table 79. GlaxoSmithKline Business Overview Table 80. GlaxoSmithKline Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. GlaxoSmithKline Nocturia Product Portfolio Table 82. GlaxoSmithKline Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Nocturia Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Johnson & Johnson Nocturia Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Merck Nocturia Product Portfolio Table 92. Merck Recent Development Table 93. Mylan Company Information Table 94. Mylan Business Overview Table 95. Mylan Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Mylan Nocturia Product Portfolio Table 97. Mylan Recent Development Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Novartis Nocturia Product Portfolio Table 102. Novartis Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Nocturia Product Portfolio Table 107. Pfizer Recent Development Table 108. Rechon Life Science AB Company Information Table 109. Rechon Life Science AB Business Overview Table 110. Rechon Life Science AB Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Rechon Life Science AB Nocturia Product Portfolio Table 112. Rechon Life Science AB Recent Development Table 113. Sagent Pharmaceuticals Company Information Table 114. Sagent Pharmaceuticals Business Overview Table 115. Sagent Pharmaceuticals Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Sagent Pharmaceuticals Nocturia Product Portfolio Table 117. Sagent Pharmaceuticals Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Sanofi Nocturia Product Portfolio Table 122. Sanofi Recent Development Table 123. Sun Pharmaceutical Industries Ltd. Company Information Table 124. Sun Pharmaceutical Industries Ltd. Business Overview Table 125. Sun Pharmaceutical Industries Ltd. Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Sun Pharmaceutical Industries Ltd. Nocturia Product Portfolio Table 127. Sun Pharmaceutical Industries Ltd. Recent Development Table 128. Teva Company Information Table 129. Teva Business Overview Table 130. Teva Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Teva Nocturia Product Portfolio Table 132. Teva Recent Development Table 133. Chengdu Leer Pharmaceutical Company Information Table 134. Chengdu Leer Pharmaceutical Business Overview Table 135. Chengdu Leer Pharmaceutical Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Chengdu Leer Pharmaceutical Nocturia Product Portfolio Table 137. Chengdu Leer Pharmaceutical Recent Development Table 138. Fosun Pharma Company Information Table 139. Fosun Pharma Business Overview Table 140. Fosun Pharma Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Fosun Pharma Nocturia Product Portfolio Table 142. Fosun Pharma Recent Development Table 143. Hainan Zhonghe Pharmaceutical Company Information Table 144. Hainan Zhonghe Pharmaceutical Business Overview Table 145. Hainan Zhonghe Pharmaceutical Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Hainan Zhonghe Pharmaceutical Nocturia Product Portfolio Table 147. Hainan Zhonghe Pharmaceutical Recent Development Table 148. Nanjing Xingyin Pharmaceutical Group Company Information Table 149. Nanjing Xingyin Pharmaceutical Group Business Overview Table 150. Nanjing Xingyin Pharmaceutical Group Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Nanjing Xingyin Pharmaceutical Group Nocturia Product Portfolio Table 152. Nanjing Xingyin Pharmaceutical Group Recent Development Table 153. Hybio Pharmaceutical Company Information Table 154. Hybio Pharmaceutical Business Overview Table 155. Hybio Pharmaceutical Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Hybio Pharmaceutical Nocturia Product Portfolio Table 157. Hybio Pharmaceutical Recent Development Table 158. Zhejiang Conba Pharmaceutical Company Information Table 159. Zhejiang Conba Pharmaceutical Business Overview Table 160. Zhejiang Conba Pharmaceutical Nocturia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Zhejiang Conba Pharmaceutical Nocturia Product Portfolio Table 162. Zhejiang Conba Pharmaceutical Recent Development Table 163. North America Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 164. North America Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 165. North America Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 166. North America Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 167. North America Nocturia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 168. North America Nocturia Revenue by Country (2021-2026) & (US$ Million) Table 169. North America Nocturia Revenue by Country (US$ Million) & (2027-2032) Table 170. Europe Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 171. Europe Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 172. Europe Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 173. Europe Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 174. Europe Nocturia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. Europe Nocturia Revenue by Country (2021-2026) & (US$ Million) Table 176. Europe Nocturia Revenue by Country (US$ Million) & (2027-2032) Table 177. China Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 178. China Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 179. China Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 180. China Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 181. Asia Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 182. Asia Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 183. Asia Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 184. Asia Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 185. Asia Nocturia Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 186. Asia Nocturia Revenue by Region (US$ Million) & (2021-2026) Table 187. Asia Nocturia Revenue by Region (US$ Million) & (2027-2032) Table 188. SAMEA Nocturia Revenue by Type (2021-2026) & (US$ Million) Table 189. SAMEA Nocturia Revenue by Type (2027-2032) & (US$ Million) Table 190. SAMEA Nocturia Revenue by Application (2021-2026) & (US$ Million) Table 191. SAMEA Nocturia Revenue by Application (2027-2032) & (US$ Million) Table 192. SAMEA Nocturia Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 193. SAMEA Nocturia Revenue by Country (2021-2026) & (US$ Million) Table 194. SAMEA Nocturia Revenue by Country (US$ Million) & (2027-2032) Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. Nocturia Image Figure 2. Global Nocturia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nocturia Market Size Share 2021 VS 2025 VS 2032 Figure 4. Desmopressin Image Figure 5. Diuretics Image Figure 6. Anticholinergic Drugs Image Figure 7. Alpha Blockers Image Figure 8. Others Image Figure 9. Global Nocturia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Nocturia Market Size Share 2021 VS 2025 VS 2032 Figure 11. Retail Pharmacies Image Figure 12. Online Pharmacies Image Figure 13. Hospital Pharmacies Image Figure 14. Global Nocturia Market Size (US$ Million) & (2021-2032) Figure 15. Global Nocturia Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nocturia Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nocturia Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nocturia Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nocturia Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nocturia Revenue Market Share by Type (2021-2032) Figure 22. Global Nocturia Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nocturia Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nocturia Revenue Market Share by Application (2021-2032) Figure 25. North America Nocturia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nocturia Revenue Share by Type (2021-2032) Figure 27. North America Nocturia Revenue Share by Application (2021-2032) Figure 28. North America Nocturia Revenue Share by Country (2021-2032) Figure 29. United States Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nocturia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nocturia Revenue Share by Type (2021-2032) Figure 34. Europe Nocturia Revenue Share by Application (2021-2032) Figure 35. Europe Nocturia Revenue Share by Country (2021-2032) Figure 36. Germany Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nocturia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nocturia Revenue Share by Type (2021-2032) Figure 46. China Nocturia Revenue Share by Application (2021-2032) Figure 47. Asia Nocturia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nocturia Revenue Share by Type (2021-2032) Figure 49. Asia Nocturia Revenue Share by Application (2021-2032) Figure 50. Asia Nocturia Revenue Share by Region (2021-2032) Figure 51. Japan Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nocturia Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nocturia Revenue Share by Type (2021-2032) Figure 59. SAMEA Nocturia Revenue Share by Application (2021-2032) Figure 60. SAMEA Nocturia Revenue Share by Country (2021-2032) Figure 61. Brazil Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nocturia Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Desmopressin
  • Diuretics
  • Anticholinergic Drugs
  • Alpha Blockers
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Allergan
  • APOTEX INC
  • Astellas Pharma
  • Astra Zeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Pfizer
  • Rechon Life Science AB
  • Sagent Pharmaceuticals
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva
  • Chengdu Leer Pharmaceutical
  • Fosun Pharma
  • Hainan Zhonghe Pharmaceutical
  • Nanjing Xingyin Pharmaceutical Group
  • Hybio Pharmaceutical
  • Zhejiang Conba Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nocturia Market by Type
  3. 1.2.1 Global Nocturia Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Desmopressin
  5. 1.2.3 Diuretics
  6. 1.2.4 Anticholinergic Drugs
  7. 1.2.5 Alpha Blockers
  8. 1.2.6 Others
  9. 1.3 Nocturia Market by Application
  10. 1.3.1 Global Nocturia Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Retail Pharmacies
  12. 1.3.3 Online Pharmacies
  13. 1.3.4 Hospital Pharmacies
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nocturia Market Dynamics
  1. 2.1 Nocturia Industry Trends
  2. 2.2 Nocturia Industry Drivers
  3. 2.3 Nocturia Industry Opportunities and Challenges
  4. 2.4 Nocturia Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nocturia Market Perspective (2021-2032)
  2. 3.2 Global Nocturia Growth Trends by Region
  3. 3.2.1 Global Nocturia Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nocturia Market Size by Region (2021-2026)
  5. 3.2.3 Global Nocturia Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nocturia Revenue by Players
  2. 4.1.1 Global Nocturia Revenue by Players (2021-2026)
  3. 4.1.2 Global Nocturia Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nocturia Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nocturia Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nocturia Key Players Headquarters & Area Served
  7. 4.4 Global Nocturia Players, Product Type & Application
  8. 4.5 Global Nocturia Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nocturia Market CR5 and HHI
  11. 4.6.3 2025 Nocturia Tier 1, Tier 2, and Tier 3
5 Nocturia Market Size by Type
  1. 5.1 Global Nocturia Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nocturia Revenue by Type (2021-2032)
  3. 5.3 Global Nocturia Revenue Market Share by Type (2021-2032)
6 Nocturia Market Size by Application
  1. 6.1 Global Nocturia Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nocturia Revenue by Application (2021-2032)
  3. 6.3 Global Nocturia Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abbott
  2. 7.1.1 Abbott Company Information
  3. 7.1.2 Abbott Business Overview
  4. 7.1.3 Abbott Nocturia Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abbott Nocturia Product Portfolio
  6. 7.1.5 Abbott Recent Developments
  7. 7.2 Allergan
  8. 7.2.1 Allergan Company Information
  9. 7.2.2 Allergan Business Overview
  10. 7.2.3 Allergan Nocturia Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Allergan Nocturia Product Portfolio
  12. 7.2.5 Allergan Recent Developments
  13. 7.3 APOTEX INC
  14. 7.3.1 APOTEX INC Company Information
  15. 7.3.2 APOTEX INC Business Overview
  16. 7.3.3 APOTEX INC Nocturia Revenue and Gross Margin (2021-2026)
  17. 7.3.4 APOTEX INC Nocturia Product Portfolio
  18. 7.3.5 APOTEX INC Recent Developments
  19. 7.4 Astellas Pharma
  20. 7.4.1 Astellas Pharma Company Information
  21. 7.4.2 Astellas Pharma Business Overview
  22. 7.4.3 Astellas Pharma Nocturia Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Astellas Pharma Nocturia Product Portfolio
  24. 7.4.5 Astellas Pharma Recent Developments
  25. 7.5 Astra Zeneca
  26. 7.5.1 Astra Zeneca Company Information
  27. 7.5.2 Astra Zeneca Business Overview
  28. 7.5.3 Astra Zeneca Nocturia Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Astra Zeneca Nocturia Product Portfolio
  30. 7.5.5 Astra Zeneca Recent Developments
  31. 7.6 Bristol-Myers Squibb
  32. 7.6.1 Bristol-Myers Squibb Company Information
  33. 7.6.2 Bristol-Myers Squibb Business Overview
  34. 7.6.3 Bristol-Myers Squibb Nocturia Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bristol-Myers Squibb Nocturia Product Portfolio
  36. 7.6.5 Bristol-Myers Squibb Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Nocturia Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Nocturia Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 Ferring Pharmaceuticals
  44. 7.8.1 Ferring Pharmaceuticals Company Information
  45. 7.8.2 Ferring Pharmaceuticals Business Overview
  46. 7.8.3 Ferring Pharmaceuticals Nocturia Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ferring Pharmaceuticals Nocturia Product Portfolio
  48. 7.8.5 Ferring Pharmaceuticals Recent Developments
  49. 7.9 GlaxoSmithKline
  50. 7.9.1 GlaxoSmithKline Company Information
  51. 7.9.2 GlaxoSmithKline Business Overview
  52. 7.9.3 GlaxoSmithKline Nocturia Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GlaxoSmithKline Nocturia Product Portfolio
  54. 7.9.5 GlaxoSmithKline Recent Developments
  55. 7.10 Johnson & Johnson
  56. 7.10.1 Johnson & Johnson Company Information
  57. 7.10.2 Johnson & Johnson Business Overview
  58. 7.10.3 Johnson & Johnson Nocturia Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Johnson & Johnson Nocturia Product Portfolio
  60. 7.10.5 Johnson & Johnson Recent Developments
  61. 7.11 Merck
  62. 7.11.1 Merck Company Information
  63. 7.11.2 Merck Business Overview
  64. 7.11.3 Merck Nocturia Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Merck Nocturia Product Portfolio
  66. 7.11.5 Merck Recent Developments
  67. 7.12 Mylan
  68. 7.12.1 Mylan Company Information
  69. 7.12.2 Mylan Business Overview
  70. 7.12.3 Mylan Nocturia Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Mylan Nocturia Product Portfolio
  72. 7.12.5 Mylan Recent Developments
  73. 7.13 Novartis
  74. 7.13.1 Novartis Company Information
  75. 7.13.2 Novartis Business Overview
  76. 7.13.3 Novartis Nocturia Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Novartis Nocturia Product Portfolio
  78. 7.13.5 Novartis Recent Developments
  79. 7.14 Pfizer
  80. 7.14.1 Pfizer Company Information
  81. 7.14.2 Pfizer Business Overview
  82. 7.14.3 Pfizer Nocturia Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Pfizer Nocturia Product Portfolio
  84. 7.14.5 Pfizer Recent Developments
  85. 7.15 Rechon Life Science AB
  86. 7.15.1 Rechon Life Science AB Company Information
  87. 7.15.2 Rechon Life Science AB Business Overview
  88. 7.15.3 Rechon Life Science AB Nocturia Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Rechon Life Science AB Nocturia Product Portfolio
  90. 7.15.5 Rechon Life Science AB Recent Developments
  91. 7.16 Sagent Pharmaceuticals
  92. 7.16.1 Sagent Pharmaceuticals Company Information
  93. 7.16.2 Sagent Pharmaceuticals Business Overview
  94. 7.16.3 Sagent Pharmaceuticals Nocturia Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Sagent Pharmaceuticals Nocturia Product Portfolio
  96. 7.16.5 Sagent Pharmaceuticals Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Nocturia Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Nocturia Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
  103. 7.18 Sun Pharmaceutical Industries Ltd.
  104. 7.18.1 Sun Pharmaceutical Industries Ltd. Company Information
  105. 7.18.2 Sun Pharmaceutical Industries Ltd. Business Overview
  106. 7.18.3 Sun Pharmaceutical Industries Ltd. Nocturia Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Sun Pharmaceutical Industries Ltd. Nocturia Product Portfolio
  108. 7.18.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  109. 7.19 Teva
  110. 7.19.1 Teva Company Information
  111. 7.19.2 Teva Business Overview
  112. 7.19.3 Teva Nocturia Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Teva Nocturia Product Portfolio
  114. 7.19.5 Teva Recent Developments
  115. 7.20 Chengdu Leer Pharmaceutical
  116. 7.20.1 Chengdu Leer Pharmaceutical Company Information
  117. 7.20.2 Chengdu Leer Pharmaceutical Business Overview
  118. 7.20.3 Chengdu Leer Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Chengdu Leer Pharmaceutical Nocturia Product Portfolio
  120. 7.20.5 Chengdu Leer Pharmaceutical Recent Developments
  121. 7.21 Fosun Pharma
  122. 7.21.1 Fosun Pharma Company Information
  123. 7.21.2 Fosun Pharma Business Overview
  124. 7.21.3 Fosun Pharma Nocturia Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Fosun Pharma Nocturia Product Portfolio
  126. 7.21.5 Fosun Pharma Recent Developments
  127. 7.22 Hainan Zhonghe Pharmaceutical
  128. 7.22.1 Hainan Zhonghe Pharmaceutical Company Information
  129. 7.22.2 Hainan Zhonghe Pharmaceutical Business Overview
  130. 7.22.3 Hainan Zhonghe Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Hainan Zhonghe Pharmaceutical Nocturia Product Portfolio
  132. 7.22.5 Hainan Zhonghe Pharmaceutical Recent Developments
  133. 7.23 Nanjing Xingyin Pharmaceutical Group
  134. 7.23.1 Nanjing Xingyin Pharmaceutical Group Company Information
  135. 7.23.2 Nanjing Xingyin Pharmaceutical Group Business Overview
  136. 7.23.3 Nanjing Xingyin Pharmaceutical Group Nocturia Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Nanjing Xingyin Pharmaceutical Group Nocturia Product Portfolio
  138. 7.23.5 Nanjing Xingyin Pharmaceutical Group Recent Developments
  139. 7.24 Hybio Pharmaceutical
  140. 7.24.1 Hybio Pharmaceutical Company Information
  141. 7.24.2 Hybio Pharmaceutical Business Overview
  142. 7.24.3 Hybio Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Hybio Pharmaceutical Nocturia Product Portfolio
  144. 7.24.5 Hybio Pharmaceutical Recent Developments
  145. 7.25 Zhejiang Conba Pharmaceutical
  146. 7.25.1 Zhejiang Conba Pharmaceutical Company Information
  147. 7.25.2 Zhejiang Conba Pharmaceutical Business Overview
  148. 7.25.3 Zhejiang Conba Pharmaceutical Nocturia Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Zhejiang Conba Pharmaceutical Nocturia Product Portfolio
  150. 7.25.5 Zhejiang Conba Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Nocturia Revenue (2021-2032)
  2. 8.2 North America Nocturia Revenue by Type (2021-2032)
  3. 8.2.1 North America Nocturia Revenue by Type (2021-2026)
  4. 8.2.2 North America Nocturia Revenue by Type (2027-2032)
  5. 8.3 North America Nocturia Revenue Share by Type (2021-2032)
  6. 8.4 North America Nocturia Revenue by Application (2021-2032)
  7. 8.4.1 North America Nocturia Revenue by Application (2021-2026)
  8. 8.4.2 North America Nocturia Revenue by Application (2027-2032)
  9. 8.5 North America Nocturia Revenue Share by Application (2021-2032)
  10. 8.6 North America Nocturia Revenue by Country
  11. 8.6.1 North America Nocturia Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nocturia Revenue by Country (2021-2026)
  13. 8.6.3 North America Nocturia Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Nocturia Revenue (2021-2032)
  2. 9.2 Europe Nocturia Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nocturia Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nocturia Revenue by Type (2027-2032)
  5. 9.3 Europe Nocturia Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nocturia Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nocturia Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nocturia Revenue by Application (2027-2032)
  9. 9.5 Europe Nocturia Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nocturia Revenue by Country
  11. 9.6.1 Europe Nocturia Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nocturia Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nocturia Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Nocturia Revenue (2021-2032)
  2. 10.2 China Nocturia Revenue by Type (2021-2032)
  3. 10.2.1 China Nocturia Revenue by Type (2021-2026)
  4. 10.2.2 China Nocturia Revenue by Type (2027-2032)
  5. 10.3 China Nocturia Revenue Share by Type (2021-2032)
  6. 10.4 China Nocturia Revenue by Application (2021-2032)
  7. 10.4.1 China Nocturia Revenue by Application (2021-2026)
  8. 10.4.2 China Nocturia Revenue by Application (2027-2032)
  9. 10.5 China Nocturia Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nocturia Revenue (2021-2032)
  2. 11.2 Asia Nocturia Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nocturia Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nocturia Revenue by Type (2027-2032)
  5. 11.3 Asia Nocturia Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nocturia Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nocturia Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nocturia Revenue by Application (2027-2032)
  9. 11.5 Asia Nocturia Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nocturia Revenue by Country
  11. 11.6.1 Asia Nocturia Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nocturia Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nocturia Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nocturia Revenue (2021-2032)
  2. 12.2 SAMEA Nocturia Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nocturia Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nocturia Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nocturia Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nocturia Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nocturia Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nocturia Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nocturia Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nocturia Revenue by Country
  11. 12.6.1 SAMEA Nocturia Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nocturia Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nocturia Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst